Crucell Terug naar discussie overzicht

Events

1. flosz 3 april 2010 20:24

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   quote:

   maxen schreef:

   [quote=gocrucellgo]
   Expression of Recombinant Proteins using the PER.C6 Human Cells
   ...
   Percivia, LLC
   [/quote]
   Ik dacht overigens eens: doe eens gek, kijk op de Percivia website, tabje "news en events":
   
   Laatste (!) nieuws:
   
   "29 September 2008 Groningen/Leiden, The Netherlands; Parsippany, USA,
   DSM and Crucell announce another key achievement for PER.C6® Technology; Scale up of high-titer Fed-Batch Process to 250 Liters."
   
   2008! 1 1/2 jaar geleden. Kleine moeite om de percevia presentaties, of 'open dagen/demonstraties' e.d. erop te zetten, en zo nog wat. Als je dit niet bijhoudt, kun je beter de hele sectie 'news' weghalen, want dit wekt toch echt een verkeerde indruk....
   

   Niet via de “news”-link maar de PERCIVIA R&D-link.
   
   Maart/April 2009
   High level expression of functional human IgMs in human PER.C6® cells
   www.percivia.com/researchDevt/Tchouda...
   
   May, 2009.
   Development of a High-Capacity
   MAb Capture Step Based on
   Cation-Exchange Chromatography
   www.percivia.com/researchDevt/Lain%20...
   
   Jan., 2010
   Primary Clarification of Very High-Density Cell Culture Harvests By Enhanced Cell Settling
   www.bioprocessintl.com/multimedia/arc...
   
   Feb., 2010
   Development of a polishing step using a hydrophobic interaction membrane adsorber with a PER.C6-derived recombinant antibody.
   www.ncbi.nlm.nih.gov/pubmed/19739096
   
   Mar 2, 2010
   PEG Precipitation: A Powerful Tool for Monoclonal Antibody Purification
   This alternative purification method to chromatography is readily scalable and fits a fully disposable downstream process.
   www.investorvillage.com/smbd.asp?mb=2...
   
2. [verwijderd] 3 april 2010 21:34

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   flosz schreef:

   [quote=maxen]
   Ik dacht overigens eens: doe eens gek, kijk op de Percivia website, tabje "news en events":
   ...
   [/quote]
   Niet via de “news”-link maar de PERCIVIA R&D-link:
   
   Maart/April 2009
   ...
   May, 2009.
   ...
   Jan., 2010
   ...
   Feb., 2010
   ...
   Mar 2, 2010
   ...
   

   Dank Flosz. Dus er gebeurt best wat, ook recent.
   
   't Zou m.i. een kleine moeite zijn om dan ook de 'news&events' sectie te vullen met wat publicaties/verwijzingen naar publicaties, en, doe gek, events... Wekt echt een betere indruk dan het huidige...
   
   Met kanttekening dat percivia zich meer op klanten (i.e. ontwikkelaars bij biotechs) richt dan op investeerders. Maar dan nog.
3. flosz 30 april 2010 13:50

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Preliminary Program
   (4/16/10)
   Vaccine Technology III
   June 6 - 11, 2010
   Vallarta Palace Hotel
   Nuevo Vallarta, Mexico
   
   Organizing Committee Members:
   o.a. John Lewis, Crucell, USA
   
   13:30 – 15:30
   Session VII : New Technologies
   Scale-up of an intensified process for rAD35 adenovirus production using the PER.C6® cell substrate
   Alfred Luitjens
   Crucell, Netherlands
   
   Development of a large volume high density PER.C6® cell bank
   Herman van Herk, Crucell, Netherlands
   www.engconfintl.org/10aapre.pdf
   
   THE IMMUNOTHERAPEUTICS &
   VACCINE SUMMIT
   August 17-19, 2010 • Royal Sonesta Hotel • Cambridge, MA
   
   Tuesday, August 17
   4:15 TB Vaccine Development
   Lewellys F. Barker, M.D., M.P.H., Senior Medical Advisor, Aeras Global TB Vaccine Foundation
   Much progress in TB vaccine research and development over the past decade has been accomplished through partnerships between the
   public, private, and academic sectors via nonprofit organizations like the Aeras Global TB Vaccine Foundation. The main focus is on developing a heterologous prime-boost vaccine regimen that could include a replacement
   for current BCGs such as a recombinant BCG as the prime, and boosting with one of several novel vaccine candidates, including viral vectored and
   fusion protein vaccines. A number of vaccine candidates are in clinical trials in the US, Europe and Africa, and several other candidates are in the pipeline. The goals for a new TB vaccine regimen are safety, including in people
   infected with HIV, and increased efficacy against TB disease.
   
   Tuesday, August 17
   STABILITY AND FORMULATION, AND COLLABORATION FOR
   MANUFACTURING OUTSIDE THE US AND EU
   4:15 Spray Drying in Vaccine Manufacturing for
   Improved Stability
   Tom Jin, M.D., Scientist, Principal Investigator, Technique Operations &
   Manufacturing, Aeras Global TB Vaccine Foundation
   Based on our AERAS 402 vaccine, the benefits and challenges of manufacturing spray dried products will be discussed. Shorter processing
   cycle time and larger batch size per unit operation compared with lyophilization improve the commercial application of the spray drying
   technique. However, challenges exist in transferring the concept into a final product, such as: 1) Developing a stable formulation that gives a high recovery during the spray drying process and is hydrophobic during shelf
   storage; 2) The aseptic cGMP spray dryer design; 3) Powder filling; 4) Developing economic unit-dose packs or blister capsules for final product
   and DPI; 5) Cost effectiveness.
   
   5:15 Benefits of Manufacturing Vaccines in the
   Developing World: Focus on Korea
   Bill Enright, M.A., M.Sc., President & CEO, Vaxin, Inc.
   Vaxin is developing novel, vector based, intranasally delivered vaccines
   primarily for influenza. We have shown proof of concept in Phase I studies for both seasonal and pandemic influenza. Given economic realities over the past 12-18 months, particularly in the U.S. marketplace, Vaxin looked at a number of more non-conventional sources of funding. We were able to put together a joint venture in Korea with AnC Bio. This joint venture, AnC-Vaxin, will be responsible for the manufacture of our cell culture based vaccines for the Asian marketplace. This talk will focus on the opportunities and
   challenges of setting up manufacturing in Korea.
   
   Wednesday, August 18
   7:30am Morning Coffee (Breakfast Sponsored Presentation
   Opportunity Available)
   SCALE-UP AND RAPID RESPONSE TO PANDEMICS
   
   8:30 Scale-Up of an Intensified Process for rAd35
   Adenovirus Production using the PER.C6® Cell Substrate
   Herman van Herk, M.Sc., Scientist, Up-Stream Process Development,
   Crucell Holland B.V.
   Our recombinant tuberculosis adenovirus based vaccine (rAd35) is currently in several Phase I trials with promising results, and in a recently started Phase II study. Given the uncertainties required to develop a 10,000-liter facility
   and the need to develop a 10,000L scale viral vaccine manufacturing process, we are focusing on intensification of rAd35 manufacturing using the
   PER.C6® cell substrate. We will show a 10-fold intensification at bench scale and, for the first time, results of the scaled-up upstream process in 50L single-use bioreactors and the impact on cost of goods at production scale.
   www.the-infoshop.com/conference/imvac...
   
4. [verwijderd] 30 april 2010 14:11

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   flosz schreef:

   Development of a large volume high density PER.C6® cell bank
   .....
   Herman van Herk, Crucell, Netherlands
   www.engconfintl.org/10aapre.pdf
   ....
   
   

   Familie van?
   
   :->#)
   
   Dirk
5. flosz 30 april 2010 14:14

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Herman....
6. flosz 5 mei 2010 11:32

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Optimizing Mammalian Cell Lines
   August 25-26, 2010
   Gene expression in mammalian cells is the foundation for protein production and the creation of biologics. As more protein-based products head into development, the need to refine processes for optimizing cell line development increases. Reducing the time needed to identify high-expressing clones and achieve transfection is essential for trimming a project’s overall costs.
   The Optimizing Mammalian Cell Lines meeting features experts sharing their protocols and case studies that illustrate how they have optimized cell lines to reach enhanced expression. Their insights and experiences will provide real-world details to help you conquer the challenges of cell line development. As you seek to enhance your skills and knowledge, make time to join the information exchange and network with colleagues from around the world who share common cellular goals on the path to cell line development.
   
   Wednesday, August 25
   PROTEIN EXPRESSION
   4:45 Expression of Recombinant Proteins for Human Therapeutics using the PER.C6 Human Cells
   John H. Chon, Ph.D., Senior Director, BioProcess R&D, PERCIVIA, LLC
   Today’s biopharmaceutical market requires manufacturing processes that are flexible, robust, cost-efficient, and deliver consistent product quality. PER.C6® cells have recently gained a lot of attention primarily due to the very high expression levels of recombinant monoclonal antibodies. For example, over 2 g/L of IgM and up to 13 g/L IgG production in platform fed-batch and volumetric productivity of over 27 g/L of IgG in just 2 weeks of process time using the XD® process have been reported over the past couple of years. We have successfully used this cell line to also express various recombinant proteins at high levels and with the desired quality characteristics. This presentation will describe our experiences in expressing and characterizing these recombinant proteins using the PER.C6® human cells.
   www.healthtech.com/bpd/mex
   *************
   
   
   Eerder:
   
   BIOENGINEERING IN THE BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES: FUNDAMENTAL AND REAL WORLD PERSPECTIVES
   
   The goal of this course is to offer students insight into the practical aspects of industrial bioprocessing.
   
   23-Mar: Delivering the Goods: The Role of Biomanufacturing in Providing Safe and Effective Medicines
   In addition to providing the necessary expertise to produce drugs in a safe manner, the bioprocess engineer engaged in cGMP manufacturing of human therapeutics has to be aware of the new technological and scientific information that may impact safety and efficacy of the drugs being produced themselves. This is because the manufacturing process has a major impact in the quality of the products used in human therapy. For instance, post-translational modifications of protein therapeutics could either enhance or preclude the use of these molecules. In some cases structures are desired (e.g. sialic acid), and in other cases these may be avoided (e.g. fucose) for proper or enhanced product efficacy. Also, the presence of undesired structures on the proteins and/or residual process contaminants may have a significant impact on the efficacy (e.g. increased product clearance) and even on the safety (e.g. triggering allergic or anaphylactic reactions) of the drugs. Newer findings from the post-marketing clinical surveillance of these products are being added to the collective knowledge on the safety and efficacy of biologics. These data may have a profound influence on which manufacturing approaches should be considered (or discarded) for these products. This session will provide a recent survey of the available literature on the subject and will challenge the students to examine and propose adequate technology approaches to manufacture protein therapeutics.
   Instructor: Marco A. Cacciuttolo, Ph.D.
   President and CEO, PERCIVIA LLC.
   biomedical.rutgers.edu/content/topics...
   
7. Alpen 13 oktober 2010 13:56

   auteur info

   • Alpen

     Lid sinds: 21 mei 2008

     Laatste bezoek: 10 dec 2024

   • Aanbevelingen

     Ontvangen: 815

     Gegeven: 100

   •    Aantal posts: 781

   Heeft Jaap nog wat te melden sinds publicatie van positieve resultaten van de tweede fase II op de RITA XX bijeenkomst van vorig jaar? "Start Indian Phase II on track for H2 2010" maar ondertussen wel een jaar errug stil.
   
   ---
   XXI INTERNATIONAL MEETING ON RABIES IN THE AMERICAS (RITA XXI)
   
   Guadalajara, October 17th to 22nd, 2010
   
   Scientific program and abstracts ( Programa_científico(1)[1].pdf )
   
   Tuesday, October 19th - Fourth session. Rabies immunologie.
   
   8:30 - 4. Global evaluation of neutralizing activity of CL184, a monoclonal antibody combination against rabies / W.E. Marissen, James Ellison, Michael Niezgoda, Ivan Kuzmin, Richard Franka, Gerrit Jan Weverling, Jessica Meijer, Anvar Rasuli, Régis Sodoyer, Laure Laffly, C.E. Rupprecht, J. Goudsmit.
8. aossa 13 oktober 2010 14:13

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 23 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   Naar aloude gewoonte in november een technologie update???
   
   Zal niet waar zijn, zeker !!!
   
   Mogelijk wel een BAV (maar zonder bubbels) !!!
9. Alpen 24 november 2010 16:17

   auteur info

   • Alpen

     Lid sinds: 21 mei 2008

     Laatste bezoek: 10 dec 2024

   • Aanbevelingen

     Ontvangen: 815

     Gegeven: 100

   •    Aantal posts: 781

   World Health Organization - TECHNET 2010 CONSULTATION
   30 November - 2 December 2010
   Kuala Lumpur, Malaysia
   
   30 November 2010 15:50 Putting Pentavalent vaccines into Uniject
   Yves Leurquin, Crucell
   
   www.who.int/immunization_delivery/sys...